ANI Pharmaceuticals posts updated investor presentation (Ex. 99.1)

ANI Pharmaceuticals furnished an updated investor presentation to the investor relations section of its website and attached it as Exhibit 99.1.

Accepted by SEC EDGAR 11/10/2025 - 08:45 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ANI Pharmaceuticals furnished an updated investor presentation to the investor relations section of its website and attached it as Exhibit 99.1. The presentation is dated November 2025 and may be used in meetings with investors, analysts, and others.

The materials were provided under Items 2.02 and 7.01 and are expressly designated as furnished, not filed, under the Exchange Act, and are not subject to Section 18 liabilities or incorporated into other filings unless specifically referenced.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ANIP (ANIP) announce in this 8-K?

ANIP furnished an updated investor presentation to its website and attached it as Exhibit 99.1.

When is the ANI Pharmaceuticals investor presentation dated?

The investor presentation is dated November 2025.

Where can I find the updated ANIP investor presentation?

It is available on the company’s investor relations website and is attached as Exhibit 99.1 to the 8-K.

Are the materials considered 'filed' under the Exchange Act?

No. The information under Items 2.02 and 7.01 is furnished, not filed, and not subject to Section 18 liabilities.

Which 8-K items does ANIP reference?

The company references Item 2.02 and incorporates it into Item 7.01 by reference.

How does ANIP intend to use the presentation?

The company may use it in meetings with investors, analysts, and others.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001023024FALSE00010230242025-11-102025-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 8-K 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): November 10, 2025

ANI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-31812			58-2301143
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

210 Main Street West Baudette, Minnesota			56623
(Address of principal executive offices)			(Zip Code)

Registrant's telephone number, including area code: (218) 634-3500

Not Applicable

(Former name or former address, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock			ANIP			Nasdaq Stock Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition

On November 10, 2025, ANI Pharmaceuticals, Inc. (the “Company”) published an updated investor presentation to the investor relations section of its website. The Company may use the updated presentation in various meetings with investors, analysts, and others from time to time. A copy of the investor presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*

Item 7.01 Regulation FD Disclosure

The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*

Item 9.01 Exhibits

(d)Exhibits

Exhibit No.			Description
99.1			Investor Presentation, dated November 2025
104			Cover Page Interactive Data File (embedded with the Inline XBRL document)

*The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 10, 2025			ANI PHARMACEUTICALS, INC.
			By:			/s/ Stephen P. Carey
			Name:			Stephen P. Carey
			Title:			Senior Vice President Finance and Chief Financial Officer